A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Exclusion Criteria

• •Any acute or chronic medical illness judged to be clinically significant by the Investigator and/or Sponsor medical monitor
• •Any acute or chronic bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or hepatitis C, as defined in the protocol
• •History of heart disease, neurological disease, eye disorders or gastrointestinal disorders or surgery (including cholecystectomy)
• •Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECGs or clinical laboratory tests
• •Smoking or nicotine use, drug or alcohol abuse within 6 months of starting the study